Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes
- 15 April 2011
- journal article
- research article
- Published by Wiley in American Journal Of Medical Genetics Part C-Seminars In Medical Genetics
- Vol. 157 (2), 83-89
- https://doi.org/10.1002/ajmg.c.30300
Abstract
Noonan syndrome (NS), Costello syndrome (CS), cardiofaciocutaneous syndrome (CFCS), and LEOPARD syndrome (now also referred to as Noonan syndrome with multiple lentigines or NSML) are clinically overlapping dominant disorders that are caused by mutations in RAS signaling pathway genes. The spectrum of cancer susceptibility in this group of disorders has not been studied in detail. We identified more than 1900 cases of NS, CS, CFCS, or NSML reported in the literature between 1937 and 2010; 88 cancers were reported. The most common cancers reported in 1051 NS subjects were neuroblastoma (n = 8), acute lymphoblastic leukemia (n = 8), low grade glioma (n = 6), and rhabdomyosarcoma (n = 6). These associations are biologically plausible, given that somatic RAS pathway mutations are known to occur in these specific cancers. In addition, 40 childhood cases of myeloproliferative disease were described in individuals with NS, several of whom experienced a benign course of this hematologic condition. We confirmed the previously described association between CS and cancer in 268 reported individuals: 19 had rhabdomyosarcoma, 4 had bladder cancer, and 5 had neuroblastoma. By age 20, the cumulative incidence of cancer was approximately 4% for NS and 15% for CS; both syndromes had a cancer incidence peak in childhood. The cancers described in CFCS and NSML overlapped with those reported in NS and CS. Future epidemiologic studies will be required to confirm the described cancer spectrum and to estimate precise cancer risks. Published 2011 Wiley‐Liss, Inc.Keywords
This publication has 27 references indexed in Scilit:
- Disorders of dysregulated signal traffic through the RAS‐MAPK pathway: phenotypic spectrum and molecular mechanismsAnnals of the New York Academy of Sciences, 2010
- Noonan Syndrome: Clinical Features, Diagnosis, and Management GuidelinesPediatrics, 2010
- Heterozygous Germline Mutations in the CBL Tumor-Suppressor Gene Cause a Noonan Syndrome-like PhenotypeAmerican Journal of Human Genetics, 2010
- Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemiaNature Genetics, 2010
- Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid MalignanciesJournal of Clinical Oncology, 2009
- Genetic and Pathogenetic Aspects of Noonan Syndrome and Related DisordersHormone Research in Paediatrics, 2009
- RAS signaling dysregulation in human embryonal RhabdomyosarcomaGenes, Chromosomes and Cancer, 2009
- Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemiaBlood, 2004
- Cancer incidence in persons with Fanconi anemiaBlood, 2003
- Five additional Costello syndrome patients with rhabdomyosarcoma: Proposal for a tumor screening protocolAmerican Journal of Medical Genetics, 2002